Previous 10 | Next 10 |
2024-01-08 10:13:03 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Vincerx Pharma Inc (NASDAQ: VINC), Canoo Inc (NASDAQ: GOEV), Aclarion Inc (NASDAQ: ACON), Spectaire Holdings I...
2024-01-08 07:15:09 ET More on Cellectar Biosciences Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cellectar Biosciences Historical earnings data for Cellectar Biosciences Financial information for ...
2024-01-08 06:56:58 ET DENVER, Colo., Jan. 8, 2023 ( www.247marketnews.com )- Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported, this morning, data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapy candidate for the treat...
Iopofosine tested in heavily pretreated multi-class refractory population with a median of four prior therapies and achieves 75.6% Overall Response Rate; 61% Major Response Rate ( 95% CI, 44.5%, 75.8%) ; 100% Disease Control Rate exceeding protocol statistical hurdle of 20% ...
Management to host conference call on Monday, January 8, 2024, at 8:00 am ET Company also to present at the Biotech Showcase FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on...
2023-12-26 08:22:28 ET Gainers: RayzeBio ( RYZB ) +100% on being acquired by Bristol Myers Squibb . Gracell Biotechnologies ( GRCL ) +60% to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases . IMAC Holdings ( BA...
FLORHAM PARK, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a new licensing agreement with the Wi...
FLORHAM PARK, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that is has received Notice of Allowa...
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar’...
2023-11-02 14:19:05 ET Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Conference Call November 02, 2023, 08:30 ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane Lea - CCO Andrei Shustov - SVP, Medical...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...